Navigating the Shift of Cardiac Care to ASCs: The Imperative for Data Driven Commercial Strategy

Cardiac Care Is Moving to ASCs – Is Your Commercial Strategy Prepared?

Cardiac procedures are shifting to outpatient settings and increasingly into Ambulatory Surgery Centers (ASCs). This brief flags where the move is happening first, why it matters for MedTech commercial models, and how claims-level insight helps target the right markets and accounts to revenue and capture growth while protecting against revenue loss.

Cardiac procedures continue to shift into ASCs

Procedures that once required inpatient stays are now routinely done same-day. Hospitals first pushed appropriate cases into hospital outpatient departments as devices, anesthesia, and recovery pathways improved. The next wave is the migration from HOPDs into ASCs for select procedures on the ASC Covered Procedure List. For MedTech manufacturers still built around hospital targeting and data, this shift creates both near-term exposure and a clear growth lane.

ASC adoption differs by procedure and state

ASC cardiac volume still represents a small slice of total cases but it’s rising fast in select pockets. There won’t be one national tipping point; adoption will move procedure by procedure and market by market. Clinical risk, physician comfort, and existing outpatient pathways vary across procedure and each follows a different curve. State rules matter, too: non–Certificate of Need (CON) states have generally moved faster, while CON-restricted states face higher barriers. Recent CON changes (repeal or relaxation) are opening up new growth zones while the addition of cardiac ablation procedures to the Covered Procedure List adds further momentum to an ongoing trend.

ASC ready commercial strategy depends on claims level insight

Hospital-centric sources often undercount early ASC volumes and blur the first signs of migration. Site-of-service claims data adds the facility, physician, and payer-level visibility needed to spot acceleration, track shifting referral flows, quantify at-risk revenue, and focus commercial effort.

In this white paper, you’ll learn:

• How CMS and commercial payer policy is expanding (and limiting) ASC eligibility across cardiac procedures
• Which categories (e.g., PCI, peripheral intervention, ablation, CRM, etc.) show the strongest near-term migration signals
• How adoption varies by state, and why CON laws and recent regulatory changes can make or break ASC growth
• How cardiac ASCs, office-based labs, and referral shifts are redistributing volume beyond hospitals
• How site-of-service claims uncover leading indicators and enable sharper ASC targeting and commercial planning

Complete the form below to access the white paper.